Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn's disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ENZN
- CUSIP: 29390410
- Web: enzon.com/
- Market Cap: $16.8 million
- Outstanding Shares: 44,214,000
- 50 Day Moving Avg: $0.38
- 200 Day Moving Avg: $0.31
- 52 Week Range: $0.22 - $0.50
Sales & Book Value:
- Trailing P/E Ratio: 19.00
- P/E Growth: 0.00
- Annual Revenue: $11.03 million
- Price / Sales: 1.52
- Book Value: $0.34 per share
- Price / Book: 1.12
- Net Margins: 61.77%
- Return on Equity: 128.45%
- Return on Assets: 124.59%
- Average Volume: 58,119 shs.
- Short Ratio: 1.03
Frequently Asked Questions for Enzon Pharmaceuticals (NASDAQ:ENZN)
What is Enzon Pharmaceuticals' stock symbol?
Enzon Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENZN."
How were Enzon Pharmaceuticals' earnings last quarter?
Enzon Pharmaceuticals Inc (NASDAQ:ENZN) issued its earnings results on Wednesday, August, 10th. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $2.27 million for the quarter. Enzon Pharmaceuticals had a net margin of 61.77% and a return on equity of 128.45%. View Enzon Pharmaceuticals' Earnings History.
When will Enzon Pharmaceuticals make its next earnings announcement?
Who are some of Enzon Pharmaceuticals' key competitors?
Some companies that are related to Enzon Pharmaceuticals include Can Fite Biopharma Ltd (CANF), Can Fite Biopharma Ltd (CANF), Soligenix (SNGX), Soligenix (SNGX), Mateon Therapeutics (MATN), Senesco Technologies (SVON), Windtree Therapeutics (WINT), Affymax (AFFY), CSL Limited (CSL), Cubist Pharmaceuticals (CBST), Dendreon (DNDN), DNIB Unwind (BIND), Durata Therapeutics (DRTX), Epirus Biopharmaceuticals (EPRS), Humanigen (KBIO), Idenix Pharmaceuticals (IDIX), InterMune (ITMN) and LipoScience (LPDX).
Who are Enzon Pharmaceuticals' key executives?
Enzon Pharmaceuticals' management team includes the folowing people:
- Jonathan N. Christodoro, Chairman of the Board
- Andrew D. Rackear J.D., Chief Executive Officer, Secretary
- Richard L. Feinstein, Chief Financial Officer, Vice President - Finance
- Odysseas D. Kostas M.D., Director
- Jennifer I. McNealey, Director
How do I buy Enzon Pharmaceuticals stock?
Shares of Enzon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enzon Pharmaceuticals' stock price today?
MarketBeat Community Rating for Enzon Pharmaceuticals (NASDAQ ENZN)MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Enzon Pharmaceuticals stock can currently be purchased for approximately $0.38.
Consensus Ratings for Enzon Pharmaceuticals (NASDAQ:ENZN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Enzon Pharmaceuticals (NASDAQ:ENZN)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Enzon Pharmaceuticals (NASDAQ:ENZN)Earnings History by Quarter for Enzon Pharmaceuticals (NASDAQ ENZN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017|| || || || || || || || |
|8/10/2016||Q3 2016||$0.02||$2.27 million||View||N/A|
|3/18/2013||Q4 2012||($0.11)||$10.01 million||$10.65 million||View||N/A|
Earnings Estimates for Enzon Pharmaceuticals (NASDAQ:ENZN)
Current Year EPS Consensus Estimate: $0.03 EPS
Dividend History by Quarter for Enzon Pharmaceuticals (NASDAQ ENZN)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Headline Trends for Enzon Pharmaceuticals (NASDAQ:ENZN)
Latest Headlines for Enzon Pharmaceuticals (NASDAQ:ENZN)
Enzon Pharmaceuticals (ENZN) Chart for Monday, September, 25, 2017